"We're in very much the era of Molecular Pathology at the moment, and what it means is that the sort of more traditional way of making a diagnosis for a patient was to look down the microscope, at the tissue or the cells, look at the different features of those cells, and based on what features were there make a diagnosis. But we're now able to actually go inside the cell, inside the nucleus and examine the genetic code that's present within that cell and look for changes that may have occurred to lead to that disease actually taking place and developing. And, so then potentially we can then recommend which treatments and more appropriate management that needs to be taken place as well. So, it's absolutely fundamental part of the future of our cancer diagnostic practice."
Dr Matthew Clarke introduces his focus area for the initiative: molecular pathology
For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted. Leica Biosystems and the editors hereby disclaim any liability arising directly or indirectly from the use of the content, including from any drugs, devices, techniques or procedures described in the content.
Copyright © 2021 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.